NCT06631066Completed
Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients
Source: ClinicalTrials.gov · Last updated 8 Oct 2024
Brief summary (registry, in English)
This is a phase II randomized trial comparing pathologic complete response rates in locally advanced patients recieving either neoadjuvant chemotherapy or neoadjuvant chemoradiation.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 160 (actual)
- First submitted
- 13 Aug 2024
- Start date
- 20 Oct 2021
- Primary completion date
- 10 Oct 2023
- Lead sponsor
- National Cancer Institute, Egypt
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06631066
What you commit to
- Study type: Interventional
- Participants enrolled: 160
- From 20 Oct 2021 to the primary completion date, 10 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients having contraindications to radiotherapy (e.g.: Pregnancy, history of previous chest wall, breast, or axillary irradiation)
- History of previous ipsilateral breast surgery.
Other illness
- Patients initially presenting with metastatic breast cancer.
- Inflammatory breast cancer (T4d) patients.
- Comorbidities that would affect skin healing or integrity, like uncontrolled diabetes mellitus or active autoimmune collagen or vascular diseases
Other
- Patients unfit to receive planned regimen of treatment that had a poor PS (i.e.: PS 3 and 4).
Who the study is looking for
- Female patients.
- Age: 21 years or older.
- ECOG performance status (PS) score 0 to 2.
- Locally advanced tumors (stage IIIA or above) of any subtype.
- Early breast cancer of the HER2+ or TNBC subtype when:
- Node-negative, T2 or T3.
- Node-positive, any T stage.
Age in the registry: 21 years to 65 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Institute Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.